Related Experiment Videos
Dose-dependent olanzapine-associated leukopenia: three case reports.
A Kodesh1, B Finkel, A G Lerner
1Lev Hasharon Mental Health Medical Center, Pardessya, Israel. piza@netvision.net.il
International Clinical Psychopharmacology
|March 10, 2001
Summary
Leukopenia, a dangerous side effect of antipsychotics, can be managed by reducing olanzapine dosage. This dose-dependent approach normalizes white blood cell counts, allowing continued treatment and preventing psychiatric symptom relapse.
Area of Science:
- Pharmacology
- Hematology
- Psychiatry
Background:
- Antipsychotic medications, both typical and atypical, are associated with serious hematological side effects like leukopenia and agranulocytosis.
- These adverse events can necessitate treatment discontinuation, leading to the potential return of psychiatric symptoms.
Observation:
- Three cases of patients experiencing leukopenia during olanzapine treatment are presented.
- The observed leukopenia in these patients was found to be dose-dependent.
Findings:
- Reducing the olanzapine dosage led to the normalization of white blood cell counts in all observed cases.
- This dose reduction allowed for the continuation of olanzapine therapy without the reemergence of psychiatric symptoms.
Implications:
- Leukopenia and agranulocytosis associated with olanzapine treatment may be dose-related in certain patients.
- Olanzapine dose reduction offers a viable strategy to manage hematological side effects, enabling continued treatment and potentially serving as a safer alternative to medication suspension.
- Close monitoring of white blood cell counts is crucial for patients on olanzapine.